Research suggests the investigational drug asundexian could reduce the risk of recurrent ischemic stroke in those who have recently experienced a stroke or high risk transient ischemic attack (TIA). Unlike many existing anti-clotting treatments, it did not increase major or intracranial bleeding, addressing a major limitation of current therapies.

Source: Medical News Today